In-depth Analysis of Aier Eye Hospital's Hierarchical Chain Model
Unlock More Features
Login to access AI-powered analysis, deep research reports and more advanced features

About us: Ginlix AI is the AI Investment Copilot powered by real data, bridging advanced AI with professional financial databases to provide verifiable, truth-based answers. Please use the chat box below to ask any financial question.
Related Stocks
Based on analysis of relevant data and materials, the core reasons for the continuous increase in market share of Aier Eye Hospital’s hierarchical chain model are as follows:
Aier Eye Hospital has built a four-level diagnosis and treatment network of ‘
| Level | Functional Positioning | Service Coverage |
|---|---|---|
Level 1 Hospital (Central/Provincial Capital) |
Technical guidance, diagnosis and treatment of difficult diseases, high-end surgery | Regional medical center |
Level 2 Hospital (Prefectural City) |
Regional hub, routine surgery | Whole prefectural city |
Level 3 Hospital (County Level) |
Basic diagnosis and treatment, screening and referral | County market |
Level 4 Clinic (Community) |
Eye health screening, basic services | Community end |
This structure is highly aligned with the national policy orientation of ‘
- Among the 39 institutions acquired in 2024, except for Qinghai Aier which is a provincial capital hospital, all others are prefectural and county-level institutions[2]
- By acquiring targets that are near profitability or just profitable, it controls acquisition costs while enjoying growth space [2]
- From January to September 2025, the acquired institutions achieved a total operating income of about 588 million yuan and a net profit of 20.24 million yuan [2]
- By the end of 2024, it had opened 974brand hospitals, eye centers and clinics globally (352 domestic hospitals, 229 outpatient departments, 163 overseas) [1]
- From 2014 to 2024, its revenue increased from 2.402 billion yuan to 20.982 billion yuan, an increase of more than 8 times [1]
- Its net profit attributable to parent company increased from 309 million yuan to 3.556 billion yuan, an increase of more than 11 times [1]
- Technical, management and brand advantages are effectively transformed into growth momentum for newly joined institutions [2]
- The leading driving effectof provincial capital hospitals in various provinces and regions is increasingly prominent [3]
- AI eye care layout (AierGPT digital eye care large model) improves overall diagnosis and treatment efficiency [1]
| Time Dimension | Market Share Performance | Data Source |
|---|---|---|
| 2010-2018 | Reached 35% |
Industry statistics |
| First half of 2025 | Market share increased by 9.12% , revenue 115.07 billion yuan |
Brokerage research |
| 2024 | Outpatient volume 16.94 million person-times (+12.14%), surgical volume 1.2947 million cases (+9.38%) |
Annual report |
Against the background of weak macro recovery and rational consumption,
- 1: 1 world-class eye care center
- 8: 8 national/regional eye care centers
- N: N provincial capital and prefectural city hospitals
This strategy synergizes with its international layout (141 in Europe, 18 in Southeast Asia, 1 in the US) to further strengthen its global competitiveness [1].
Aier Eye Hospital’s hierarchical chain model has achieved the following through the dual drivers of
- Efficient sinking of medical resources, filling the gap in primary eye care services
- Continuous release of scale effect, diluting unit costs
- Unified strengthening of brand awareness, improving patient trust
- Technology empowerment to improve efficiency, building long-term competitive barriers
This model effectively aligns with national medical reform policies, truly makes high-quality eye care resources accessible, thus promoting continuous increase in market share [1][2][3].
[1] Aier Eye Hospital 2024 Annual Report Summary (https://file.finance.qq.com/finance/hs/pdf/2025/04/25/1223271173.PDF)
[2] Sina Finance - “‘Eye Leader’ Accelerates Development with Another Big Move! Aier Eye Hospital Acquires 39 High-quality Hospitals for 963 Million Yuan” (https://cj.sina.com.cn/articles/view/2023821012/78a10ed402001qp6u)
[3] Guojin Medicine - In-depth Analysis of Pharmaceutical Health Industry: Standing at the Starting Point of a New Cycle (https://caifuhao.eastmoney.com/news/20251226163414024549210)
Insights are generated using AI models and historical data for informational purposes only. They do not constitute investment advice or recommendations. Past performance is not indicative of future results.
About us: Ginlix AI is the AI Investment Copilot powered by real data, bridging advanced AI with professional financial databases to provide verifiable, truth-based answers. Please use the chat box below to ask any financial question.
